vs
OCTAVE SPECIALTY GROUP INC（OSG）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是OCTAVE SPECIALTY GROUP INC的1.9倍（$194.3M vs $104.2M），REPLIGEN CORP净利率更高（4.3% vs -6.6%，领先10.9%），OCTAVE SPECIALTY GROUP INC同比增速更快（66.0% vs 14.8%），过去两年OCTAVE SPECIALTY GROUP INC的营收复合增速更高（42.9% vs 12.3%）
奥克塔夫专业集团是一家专业保险控股企业，主营定制化财产与意外伤害保险产品，核心业务聚焦超额剩余保险领域，为北美地区的商业及个人客户提供定制化风险保障解决方案。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
OSG vs RGEN — 直观对比
营收规模更大
RGEN
是对方的1.9倍
$104.2M
营收增速更快
OSG
高出51.2%
14.8%
净利率更高
RGEN
高出10.9%
-6.6%
两年增速更快
OSG
近两年复合增速
12.3%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $104.2M | $194.3M |
| 净利润 | $-6.9M | $8.3M |
| 毛利率 | — | 55.7% |
| 营业利润率 | — | 8.2% |
| 净利率 | -6.6% | 4.3% |
| 营收同比 | 66.0% | 14.8% |
| 净利润同比 | — | 42.9% |
| 每股收益（稀释后） | $-0.13 | $0.15 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OSGRGEN
| Q1 26 | $104.2M | $194.3M | ||
| Q4 25 | $66.9M | $197.9M | ||
| Q3 25 | $66.6M | $188.8M | ||
| Q2 25 | $55.0M | $182.4M | ||
| Q1 25 | $62.8M | $169.2M | ||
| Q4 24 | $65.2M | $174.1M | ||
| Q3 24 | $70.0M | $154.9M | ||
| Q2 24 | $51.0M | $154.1M |
净利润OSGRGEN
| Q1 26 | $-6.9M | $8.3M | ||
| Q4 25 | $-29.7M | $13.3M | ||
| Q3 25 | $-112.6M | $14.9M | ||
| Q2 25 | $-72.7M | $14.9M | ||
| Q1 25 | $-44.7M | $5.8M | ||
| Q4 24 | $-20.9M | $-30.3M | ||
| Q3 24 | $-27.5M | $-654.0K | ||
| Q2 24 | $-750.0K | $3.3M |
毛利率OSGRGEN
| Q1 26 | — | 55.7% | ||
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% |
营业利润率OSGRGEN
| Q1 26 | — | 8.2% | ||
| Q4 25 | -76.7% | 9.0% | ||
| Q3 25 | -48.2% | 8.9% | ||
| Q2 25 | -41.8% | 7.6% | ||
| Q1 25 | -24.1% | 3.9% | ||
| Q4 24 | -55.5% | -17.7% | ||
| Q3 24 | -29.7% | -5.1% | ||
| Q2 24 | -28.9% | 1.0% |
净利率OSGRGEN
| Q1 26 | -6.6% | 4.3% | ||
| Q4 25 | -73.8% | 6.7% | ||
| Q3 25 | -169.1% | 7.9% | ||
| Q2 25 | -132.3% | 8.2% | ||
| Q1 25 | -71.3% | 3.4% | ||
| Q4 24 | -55.1% | -17.4% | ||
| Q3 24 | -39.3% | -0.4% | ||
| Q2 24 | -1.5% | 2.2% |
每股收益（稀释后）OSGRGEN
| Q1 26 | $-0.13 | $0.15 | ||
| Q4 25 | $-0.82 | $0.24 | ||
| Q3 25 | $-2.35 | $0.26 | ||
| Q2 25 | $-1.54 | $0.26 | ||
| Q1 25 | $-1.22 | $0.10 | ||
| Q4 24 | $-11.75 | $-0.55 | ||
| Q3 24 | $-0.63 | $-0.01 | ||
| Q2 24 | $-0.02 | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $582.6M |
| 总债务越低越好 | $117.1M | — |
| 股东权益账面价值 | $833.6M | — |
| 总资产 | $2.3B | $2.9B |
| 负债/权益比越低杠杆越低 | 0.14× | — |
8季度趋势，按日历期对齐
现金及短期投资OSGRGEN
| Q1 26 | — | $582.6M | ||
| Q4 25 | $146.4M | $767.6M | ||
| Q3 25 | $27.5M | $748.7M | ||
| Q2 25 | $22.5M | $708.9M | ||
| Q1 25 | $34.1M | $697.2M | ||
| Q4 24 | $157.2M | $757.4M | ||
| Q3 24 | $40.8M | $784.0M | ||
| Q2 24 | $14.6M | $809.1M |
总债务OSGRGEN
| Q1 26 | $117.1M | — | ||
| Q4 25 | $117.6M | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | $525.6M | ||
| Q3 24 | $518.0M | — | ||
| Q2 24 | $515.0M | — |
股东权益OSGRGEN
| Q1 26 | $833.6M | — | ||
| Q4 25 | $715.8M | $2.1B | ||
| Q3 25 | $843.4M | $2.1B | ||
| Q2 25 | $859.8M | $2.1B | ||
| Q1 25 | $852.2M | $2.0B | ||
| Q4 24 | $798.4M | $2.0B | ||
| Q3 24 | $1.5B | $2.0B | ||
| Q2 24 | $1.4B | $2.0B |
总资产OSGRGEN
| Q1 26 | $2.3B | $2.9B | ||
| Q4 25 | $2.2B | $2.9B | ||
| Q3 25 | $2.1B | $2.9B | ||
| Q2 25 | $8.5B | $2.9B | ||
| Q1 25 | $8.3B | $2.9B | ||
| Q4 24 | $8.1B | $2.8B | ||
| Q3 24 | $9.3B | $2.8B | ||
| Q2 24 | $8.2B | $2.9B |
负债/权益比OSGRGEN
| Q1 26 | 0.14× | — | ||
| Q4 25 | 0.16× | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | 0.27× | ||
| Q3 24 | 0.35× | — | ||
| Q2 24 | 0.38× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OSG
| Commissions | $68.2M | 65% |
| Other | $20.6M | 20% |
| Servicing and other fees | $9.4M | 9% |
| Program fees | $3.6M | 3% |
| Investment income | $2.4M | 2% |
RGEN
| Product | $194.2M | 100% |
| Royalty and other revenue | $44.0K | 0% |
